June 13 (Reuters) - GSK said on Friday the
European Medicines Agency had accepted the drugmaker's
application to expand the use of its respiratory syncytial virus
vaccine, Arexvy, to include adults from 18 years of age.
A decision by the European Union's health regulator on the
vaccine, already approved for certain age groups, is expected in
the first half of 2026, GSK said.